These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15842308)

  • 21. Reports of hyperkalemia after publication of RALES--a pharmacovigilance study.
    Hauben M; Reich L; Gerrits CM
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):775-83. PubMed ID: 16804951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Legal constraints in EU product labelling to mitigate the environmental risk of veterinary medicines at use.
    Montforts MH; van Rijswick HF; de Haes HA
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):327-35. PubMed ID: 15546687
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Summary of adverse event reports for veterinary biologic products received by the USDA from 1999 through 2005.
    Frana TS; Elsken LA; Karli SA
    J Am Vet Med Assoc; 2006 Oct; 229(7):1100-2. PubMed ID: 17014356
    [No Abstract]   [Full Text] [Related]  

  • 24. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of suspected adverse reactions surveillance scheme.
    Skilton D
    Vet Rec; 2002 Feb; 150(7):223. PubMed ID: 11878447
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).
    Bahri P; Tsintis P
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):377-87. PubMed ID: 15517542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacovigilance in Clinical Trials: Current Practice and Challenges.
    Cheaib N
    Account Res; 2016; 23(1):23-30. PubMed ID: 26528639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic adverse drug reactions: a preliminary report from the regional pharmacovigilance center, western Nepal.
    P S; P M; Pr S
    Pak J Pharm Sci; 2008 Oct; 21(4):465-7. PubMed ID: 18930872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Causal or casual? The role of causality assessment in pharmacovigilance.
    Meyboom RH; Hekster YA; Egberts AC; Gribnau FW; Edwards IR
    Drug Saf; 1997 Dec; 17(6):374-89. PubMed ID: 9429837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel.
    Macedo AF; Marques FB; Ribeiro CF; Teixeira F
    Pharmacoepidemiol Drug Saf; 2005 Dec; 14(12):885-90. PubMed ID: 16059869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of adverse drug reaction reporting in veterinary and human medicine.
    Bukowski JA; Wartenberg D
    J Am Vet Med Assoc; 1996 Jul; 209(1):40-5. PubMed ID: 8926206
    [No Abstract]   [Full Text] [Related]  

  • 33. The evolution of safety assessments for veterinary medicinal products in the European Union.
    Woodward K
    Vet Hum Toxicol; 2004 Aug; 46(4):199-205. PubMed ID: 15303395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Vaccinovigilance: Reported adverse reactions of immunological veterinary medicinal products in 2018].
    Rogger P; Herrmann N; Ottiger H
    Schweiz Arch Tierheilkd; 2019 May; 161(5):299-306. PubMed ID: 31064736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EU pharmacovigilance guidelines. Review.
    Fletcher AP
    Adverse Drug React Toxicol Rev; 2000 Jun; 19(2):123-6. PubMed ID: 10967747
    [No Abstract]   [Full Text] [Related]  

  • 36. Adverse drug reactions among children over a 10-year period.
    Le J; Nguyen T; Law AV; Hodding J
    Pediatrics; 2006 Aug; 118(2):555-62. PubMed ID: 16882807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Causality assessment in pharmacovigilance: The French method and its successive updates.
    Miremont-Salamé G; Théophile H; Haramburu F; Bégaud B
    Therapie; 2016 Apr; 71(2):179-86. PubMed ID: 27080836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Reported adverse reactions due to veterinary drugs in 2006].
    Müntener CR; Bruckner L; Gassner B; Stürer A; Demuth DC; Althaus FR; Zwahlen R
    Schweiz Arch Tierheilkd; 2007 Oct; 149(10):439-48. PubMed ID: 17983016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Vigilance for veterinary medicinal products: declarations of adverse reactions in the year 2010].
    Müntener CR; Bruckner L; Stürer A; Althaus FR; Caduff-Janosa P
    Schweiz Arch Tierheilkd; 2012 Feb; 154(2):57-65. PubMed ID: 22287137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Vigilance for veterinary medicinal products: declarations of suspected adverse reactions in the year 2007].
    Müntener CR; Bruckner L; Stürer A; Althaus FR; Schneider A
    Schweiz Arch Tierheilkd; 2009 Jan; 151(1):12-20. PubMed ID: 19160166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.